다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

VSTM

Verastem (VSTM)

Verastem Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:VSTM

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/24	20:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VSTM	Verastem Inc
2024/05/24	20:00	Business Wire	Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer	NASDAQ:VSTM	Verastem Inc
2024/05/24	06:24	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VSTM	Verastem Inc
2024/05/24	06:01	Business Wire	Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer	NASDAQ:VSTM	Verastem Inc
2024/05/10	05:08	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VSTM	Verastem Inc
2024/05/10	05:02	Business Wire	Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates	NASDAQ:VSTM	Verastem Inc
2024/05/07	20:30	Business Wire	Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference	NASDAQ:VSTM	Verastem Inc
2024/04/19	05:05	Business Wire	Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer	NASDAQ:VSTM	Verastem Inc
2024/04/04	20:30	Business Wire	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:VSTM	Verastem Inc
2024/03/18	20:00	Business Wire	Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer	NASDAQ:VSTM	Verastem Inc
2024/03/15	05:05	Business Wire	Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates	NASDAQ:VSTM	Verastem Inc
2024/03/12	06:07	Edgar (US Regulatory)	Form SC TO-I/A - Tender offer statement by Issuer: [Amend]	NASDAQ:VSTM	Verastem Inc
2024/03/11	20:30	Business Wire	Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs	NASDAQ:VSTM	Verastem Inc
2024/03/06	07:27	Business Wire	Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer	NASDAQ:VSTM	Verastem Inc
2024/03/06	06:30	Business Wire	Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024	NASDAQ:VSTM	Verastem Inc
2024/02/09	06:22	Edgar (US Regulatory)	Form SC TO-I - Tender offer statement by Issuer	NASDAQ:VSTM	Verastem Inc
2024/02/02	23:49	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:VSTM	Verastem Inc
2024/01/30	06:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VSTM	Verastem Inc
2024/01/29	21:00	Business Wire	Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers	NASDAQ:VSTM	Verastem Inc
2024/01/19	21:54	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VSTM	Verastem Inc
2024/01/19	06:00	Business Wire	Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)	NASDAQ:VSTM	Verastem Inc
2024/01/11	21:00	Business Wire	Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference	NASDAQ:VSTM	Verastem Inc
2024/01/10	06:03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
2024/01/09	06:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VSTM	Verastem Inc
2024/01/05	21:00	Business Wire	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:VSTM	Verastem Inc
2023/12/29	06:04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
2023/12/22	06:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
2023/12/21	06:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
2023/12/21	06:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VSTM	Verastem Inc
2023/12/20	06:01	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:VSTM	Verastem Inc

검색 관련기사 보기:NASDAQ:VSTM

1 2 3 4 5 6 7 8 9 10 다음 >>

Societe Generale Effekten

Hsbc Dw Sus Etf

Lyxor ETF S&P 500 VLI

PIMCO Inflation Response...

Jpmorgan Prime Money Market Fund

BNP Paribas Issuance

Callinex Mines (QX)

Credit Acceptance

Merida Merger Corporatio...

IFS Global Software

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관